THE 21-GENE ASSAY IN THE DECISION IMPACT ASSESSMENT OF ER+, HER2- BREAST CANCER- A FRENCH REAL LIFE PROSPECTIVE STUDY
Author(s)
Mouysset J1, Laplaige P2, Fignon A3, Jallais L4, Lafuma A5, Michaud P6, Dohollou N7, Gligorov J8
1Clinique Rambot-Provençale, Aix en Provence, France, 2Polyclinique de Blois, La Chaussee St Victor, France, 3Clinique de l'Alliance, St-Cyr-sur-Loire, France, 4Tours, Tours, France, 5Cemka-Eval, Bourg La Reine, France, 6OncoCentre, Orleans, France, 7Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France, 8APHP, Tenon Hospital, Paris, France
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PMD5
Topic
Epidemiology & Public Health
Topic Subcategory
Disease Classification & Coding
Disease
Oncology
Your browser is out-of-date
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now